Outputs

See all our project outputs below, and individual staff pages for team members on the About page. The list is updated regularly.

Articles, books, and chapters

• Hanchard, M. (2022/forthcoming) ‘Issue-networks as omitted publics in the construction of #rarediseaseday discourse’, Wellcome Open Research, (TBC)TBC, pp. TBC. doi: TBC.
• Ding, J., Baumers, M., Clark, E. A., & Wildman, R. (2021) 'The economics of additive manufacturing: Towards a general cost model including process failure'. International Journal of Production Economics, 237, 108087.
• Hanchard, M. (2021) ‘The construction of rare disease discourse on YouTube: highlighting a disparity between policy rhetoric and patient practices around public engagement’, Wellcome Open Research, 6(361), doi: 10.12688/wellcomeopenres.17324.1

Conference talks and posters

• Hanchard, M. (2022) Models of data deposition. OpenFest, University of Sheffield: Sheffield, OpenFest, 14-Sep-2022
• Hanchard, M. (2022) ‘TBC’, Social Network Analysis in Scotland (SNAS) group seminar, Wong, M. (Chair). University of Edinburgh: Edinburgh, 08-Mar-2022.
• Ding, J. (2021). ‘Comparing the landscape of orphan drug developments in the US and the EU’, in Weiner, K.. (Chair) Science Technology and Medicine in Society (STEMiS) new staff seminar. Sheffield: University of Sheffield. 01-Dec-2021.
• Hanchard, M. (2021)  ‘My journey from photography to pharmaceutical policy via maps, films, and benches’, in Weiner, K. (Chair) Science Technology and Medicine in Society (STEMiS) new staff seminar. Sheffield: University of Sheffield. 01-Dec-2021.
• Hilberg, E. (2021) ‘Biopolitics at the intersection of health and law’, in Weiner, K.. (Chairs) Science Technology and Medicine in Society (STEMiS) new staff seminar. Sheffield: University of Sheffield. 01-Dec-2021.
• Ding, J. (2021).The Evolution and Dynamics of Orphan Drug Innovation in the US, in Kleinhout-Vliek,T.,(Chair) 4S Annual Meeting: Transforming the Development & Governance of Pharmaceuticals II. Toronto: Virtual. 08-Oct-2021
• Hanchard, M. (2021) 'Mapping a controversy: Identifying issue publics through discourse and social network analyses of #rarediseaseday', in: Kleinhout-Vliek,T. (Chair) 4S Annual Meeting: Transforming the Development & Governance of Pharmaceuticals III. Toronto: Virtual. 08-Oct-2021.
• Martin, P. (2021). Building the future of gene therapy: the challenge of delivering, valuing, and assessing novel biological medicines, in Kleinhout-Vliek,T. (Chair) 4S Annual Meeting: Transforming the Development & Governance of Pharmaceuticals II. Toronto: Virtual. 08-Oct-2021
• Ding, J. (2021). ‘The future is bespoke: 3D printing- a game changing technology for  drug manufacturing’, The Statesman - India. 6-Oct-2021
• Ding, J. (2021) ‘Why do we need 3D printed pharmaceuticals’, Pop-up University-Sheffield. 18,19-September-2021.
• Ding, J. (2021) ‘Pharmaprojects Demonstration’, Health Division OECD. 8-June-2021.
• Hilberg, E. (2021). TITLE, in Kleinhout-Vliek,T.,(Chair) 4S Annual Meeting: Transforming the Development & Governance of Pharmaceuticals III. Toronto: Virtual. 08-Oct-2021
• Ding, J. (2021) ‘Fixing the broken model: AI, rare disease patient organisations and the repurposing of orphan drugs’, in Fair Medicine and Artificial Intelligence: Chances, Challenges, Consequences. 3-5-March-2021.

Reports and Policy briefs

Coming soon

Online content

Coming soon